Tyra Biosciences (TYRA) Cash from Investing Activities (2020 - 2026)

Tyra Biosciences has reported Cash from Investing Activities for 7 years, with the latest figure at -$120.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 475.46% year-over-year to -$120.2 million; the trailing twelve-month figure through Mar 2026 stood at -$79.8 million (up 5.5% YoY), and the FY2025 full-year result was $72.5 million, up 173.64% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$120.2 million, down from $34.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $34.4 million in Q4 2025, with the low at -$145.0 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$17.1 million across 5 years, with a median of -$43000.0 in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 687700.0% — and 2024, when it surged 44180.49%.
• Tyra Biosciences' Cash from Investing Activities stood at -$21000.0 in 2022, then plunged by 687700.0% to -$144.4 million in 2023, then jumped by 104.82% to $7.0 million in 2024, then surged by 394.06% to $34.4 million in 2025, then sank by 449.78% to -$120.2 million in 2026.
• The last three Cash from Investing Activities figures came in at -$120.2 million (Q1 2026), $34.4 million (Q4 2025), and -$14.8 million (Q3 2025), per Business Quant data.